Enhancing the antischistosomal activity of carvacryl acetate using nanoemulsion

Papers of special note have been highlighted as: • of interest

References

• 1. Mawa PA, Kincaid-Smith J, Tukahebwa EM, Webster JP, Wilson S. Schistosomiasis morbidity hotspots: roles of the human host, the parasite and their interface in the development of severe morbidity. Front. Immunol. 12, 1–21 (2021).
  Google Scholar
• 2. Deol AK, Fleming FM, Calvo-Urbano B et al. Schistosomiasis – assessing progress toward the 2020 and 2025 global goals. N. Engl. J. Med. 381(26), 2519–2528 (2019).
  MedlineGoogle Scholar
• 3. McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ, Zhou XN. Schistosomiasis. Nat. Rev. Dis. Prim. 4(1), 1–19 (2018). • Important review on schistosomiasis, which addresses the epidemiology, pathological mechanisms and possible treatments.
  MedlineGoogle Scholar
• 4. WHO. Schistosomiasis (2022). www.who.int/news-room/fact-sheets/detail/schistosomiasis
  Google Scholar
• 5. Nelwan ML. Schistosomiasis: life cycle, diagnosis, and control. Curr. Ther. Res. Clin. Exp. 91(24), 5–9 (2019).
  MedlineGoogle Scholar
• 6. Kabuyaya M, Chimbari MJ, Mukaratirwa S. Efficacy of praziquantel treatment regimens in pre-school and school aged children infected with schistosomiasis in sub-Saharan Africa: a systematic review. Infect. Dis. Poverty 7(1), 1–7 (2018).
  MedlineGoogle Scholar
• 7. Yu QF, Zhang JY, Sun MT et al. In vivo praziquantel efficacy of Schistosoma japonicum over time: a systematic review and meta-analysis. Acta Trop. 222, 1–7 (2021).
  Google Scholar
• 8. Bergquist R, Elmorshedy H. Artemether and praziquantel: origin, mode of action, impact, and suggested application for effective control of human schistosomiasis. Trop. Med. Infect. Dis. 3(4), 1–13 (2018).
  Google Scholar
• 9. Spangenberg T. Alternatives to praziquantel for the prevention and control of schistosomiasis. ACS Infect. Dis. 7(5), 939–942 (2021).
  Medline CASGoogle Scholar
• 10. Alonso D, Muñoz J, Gascón J, Valls ME, Corachan M. Short report: failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection. Am. J. Trop. Med. Hyg. 74(2), 342–344 (2006).
  MedlineGoogle Scholar
• 11. Melman SD, Steinauer ML, Cunningham C et al. Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLOS Negl. Trop. Dis. 3(8), 1–10 (2009).
  Google Scholar
• 12. Mwangi IN, Sanchez MC, Mkoji GM et al. Praziquantel sensitivity of Kenyan Schistosoma mansoni isolates and the generation of a laboratory strain with reduced susceptibility to the drug. Int. J. Parasitol. Drugs Drug Resist. 4(3), 296–300 (2014).
  MedlineGoogle Scholar
• 13. Mengarda AC, Iles B, João JP, de Moraes J. Recent trends in praziquantel nanoformulations for helminthiasis treatment. Expert Opin. Drug Deliv. 19(4), 383–393 (2022).
  Medline CASGoogle Scholar
• 14. WHO. Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030. Geneva. www.who.int/publications/i/item/9789240010352 (2020).
  Google Scholar
• 15. André WPP, Junior JRP, Cavalcante GS et al. Carvacryl acetate nanoencapsulated with chitosan/chichá gum exhibits reduced toxicity in mice and decreases the fecal egg count of sheep infected with gastrointestinal nematodes. Parasitology 19(4), 383–393 (2021).
  Google Scholar
• 16. André WPP, de Paiva Junior JR, Cavalcante GS et al. Anthelmintic activity of nanoencapsulated carvacryl acetate against gastrointestinal nematodes of sheep and its toxicity in rodents. Rev. Bras. Parasitol. Vet. 29(1), 3837–3844 (2020).
  Google Scholar
• 17. Andre WPP, Ribeiro WLC, Cavalcante GS et al. Comparative efficacy and toxic effects of carvacryl acetate and carvacrol on sheep gastrointestinal nematodes and mice. Vet. Parasitol. 218, 52–58 (2016). • Evaluates the anthelmintic activity of carvacryl acetate in another parasite model.
  Medline CASGoogle Scholar
• 18. Moraes J, Carvalho AAL, Nakano E et al. Anthelmintic activity of carvacryl acetate against Schistosoma mansoni. Parasitol. Res. 112(2), 603–610 (2013). • Presents the synthesis of carvacryl acetate and evaluates its effect against Schistosoma mansoni.
  MedlineGoogle Scholar
• 19. Silva BC, Mengarda AC, Rodrigues VC et al. Efficacy of carvacryl acetate in vitro and following oral administration to mice harboring either prepatent or patent Schistosoma mansoni infections. Parasitol. Res. 120(11), 3837–3844 (2021).
  MedlineGoogle Scholar
• 20. McClements DJ. Advances in edible nanoemulsions: digestion, bioavailability, and potential toxicity. Prog. Lipid Res. 81, 1–11 (2021).
  Google Scholar
• 21. Jafari SM, McClements DJ. Chapter one – nanotechnology approaches for increasing nutrient bioavailability. Adv. Food Nutr. Res. 81, 1–30, doi: 10.1016/bs.afnr.2016.12.008 (2017) (Online).
  MedlineGoogle Scholar
• 22. Moraes-Lovison M, Marostegan LFP, Peres MS et al. Nanoemulsions encapsulating oregano essential oil: production, stability, antibacterial activity and incorporation in chicken pâté. Lebensm. Wiss. Technol. 77, 233–240 (2017).
  CASGoogle Scholar
• 23. Chuesiang P, Siripatrawan U, Sanguandeekul R, McClements DJ, McLandsborough L. Antimicrobial activity of PIT-fabricated cinnamon oil nanoemulsions: effect of surfactant concentration on morphology of foodborne pathogens. Food Control 98, 405–411 (2019).
  CASGoogle Scholar
• 24. Xavier ES, de Souza RL, Rodrigues VC et al. Therapeutic efficacy of carvacrol-loaded nanoemulsion in a mouse model of schistosomiasis. Front. Pharmacol. 13(June), 1–9 (2022). • Shows that nanoemulsification of carvacrol improved the biological activity of the oil.
  CASGoogle Scholar
• 25. Felício IM, Souza RL, Melo CO et al. Development and characterization of a carvacrol nanoemulsion and evaluation of its antimicrobial activity against selected food-related pathogens. Lett. Appl. Microbiol. 72(3), 299–306 (2021).
  MedlineGoogle Scholar
• 26. Dantas AGB, Souza RL, Almeida AR et al. Development, characterization, and immunomodulatory evaluation of carvacrol-loaded nanoemulsion. Molecules 26(13), 3899 (2021).
  Medline CASGoogle Scholar
• 27. Mathela CS, Singh KK, Gupta V. Synthesis and in vitro antibacterial activity of new oxoethylthio-1,3,4-oxadiazole derivatives. Acta Pol. Pharm. Drug Res. 67(4), 375–380 (2010).
  Medline CASGoogle Scholar
• 28. Laxmi M, Bhardwaj A, Mehta S, Mehta A. Development and characterization of nanoemulsion as carrier for the enhancement of bioavailability of artemether. Artif. Cells Nanomedicine Biotechnol. 43(5), 334–344 (2015).
  Medline CASGoogle Scholar
• 29. Lago EM, Silva MP, Queiroz TG et al. Phenotypic screening of nonsteroidal anti-inflammatory drugs identified mefenamic acid as a drug for the treatment of schistosomiasis. EBioMedicine 43, 370–379 (2019).
  MedlineGoogle Scholar
• 30. Brito MG, Mengarda AC, Oliveira GL et al. Therapeutic effect of diminazene aceturate on parasitic blood fluke Schistosoma mansoni infection. Antimicrob. Agents Chemother. 64(11), 1–11 (2020).
  Google Scholar
• 31. De Almeida LMS, De Carvalho LSA, Gazolla MC et al. Flavonoids and sesquiterpene lactones from Artemisia absinthium and Tanacetum parthenium against Schistosoma mansoni worms. Evid. Based Complement. Altern. Med. 2016, 7–9 (2016).
  Google Scholar
• 32. Mafud AC, Silva MPN, Nunes GBL et al. Antiparasitic, structural, pharmacokinetic, and toxicological properties of riparin derivatives. Toxicol. Vitr. 50, 1–10 (2018).
  Medline CASGoogle Scholar
• 33. Sessa DP, Mengarda AC, Simplicio PE, Antar GM, Lago JHG, De Moraes J. 15β-Senecioyl-oxy-ent-kaur-16-en-19-oic acid, a diterpene isolated from Baccharis lateralis, as promising oral compound for the treatment of schistosomiasis. J. Nat. Prod. 83(12), 3744–3750 (2020).
  Medline CASGoogle Scholar
• 34. Roquini DB, Silva GL, Ferreira LLG, Andricopulo AD, Wilairatana P, De Moraes J. Susceptibility of Angiostrongylus cantonensis larvae to anthelmintic drugs. Front. Pharmacol. 13, 1–9 (2022).
  Google Scholar
• 35. Brito JR, Wilairatana P, Roquini DB et al. Neolignans isolated from Saururus cernuus L. (Saururaceae) exhibit efficacy against Schistosoma mansoni. Sci. Rep. 12(1), 1–12 (2022).
  MedlineGoogle Scholar
• 36. Guerra RA, Silva MP, Silva TC et al. In vitro and in vivo studies of spironolactone as an antischistosomal drug capable of clinical repurposing. Antimicrob. Agents Chemother. 63(3), 1–11 (2019).
  Google Scholar
• 37. Roquini DB, Cogo RM, Mengarda AC et al. Promethazine exhibits antiparasitic properties in vitro and reduces worm burden, egg production, hepatomegaly, and splenomegaly in a schistosomiasis animal model. Antimicrob. Agents Chemother. 63(12), 1–10 (2019).
  Google Scholar
• 38. Guimarães MA, De Oliveira RN, De Almeida RL et al. Epiisopilosine alkaloid has activity against schistosoma mansoni in mice without acute toxicity. PLOS ONE 13(5), 1–19 (2018).
  Google Scholar
• 39. Porto R, Mengarda AC, Cajas RA et al. Antiparasitic properties of cardiovascular agents against human intravascular parasite Schistosoma mansoni. Pharmaceuticals 14(7), 1–15 (2021).
  Google Scholar
• 40. Mengarda AC, Silva MP, Cirino ME et al. Licarin A, a neolignan isolated from Nectandra oppositifolia Nees & Mart. (Lauraceae), exhibited moderate preclinical efficacy against Schistosoma mansoni infection. Phyther. Res. 35(9), 5154–5162 (2021).
  Medline CASGoogle Scholar
• 41. Amorim CR, Pavani TFA, Lopes AFS et al. Schiff bases of 4-phenyl-2-aminothiazoles as hits to new antischistosomals: synthesis, in vitro, in vivo and in silico studies. Eur. J. Pharm. Sci. 150, 105371 (2020).
  Medline CASGoogle Scholar
• 42. Morais CS, Mengarda AC, Miguel FB et al. Pyrazoline derivatives as promising novel antischistosomal agents. Sci. Rep. 11(1), 1–13 (2021).
  MedlineGoogle Scholar
• 43. Kumar N, Mandal A. Surfactant stabilized oil-in-water nanoemulsion: stability, interfacial tension, and rheology study for enhanced oil recovery application. Energy Fuels 32(6), 6452–6466 (2018).
  CASGoogle Scholar
• 44. Lago EM, Xavier RP, Teixeira TR, Silva LM, Da Silva Filho AA, De Moraes J. Antischistosomal agents: state of art and perspectives. Future Med. Chem. 10(1), 89–120 (2018).
  Medline CASGoogle Scholar
• 45. Radwan A, El-Lakkany NM, William S et al. A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection. Parasites and Vectors 12(1), 1–12 (2019).
  Medline CASGoogle Scholar
• 46. Crellen T, Walker M, Lamberton PHL et al. Reduced efficacy of praziquantel against Schistosoma mansoni is associated with multiple rounds of mass drug administration. Clin. Infect. Dis. 63(9), 1151–1159 (2016).
  Medline CASGoogle Scholar
• 47. Zwang J, Olliaro P. Efficacy and safety of praziquantel 40 mg/kg in preschool-aged and school-aged children: a meta-analysis. Parasit. Vectors 10(1), 1–16 (2017).
  MedlineGoogle Scholar
• 48. Ferreira LLG, de Moraes J, Andricopulo AD. Approaches to advance drug discovery for neglected tropical diseases. Drug Discov. Today 27(8), 2278–2287 (2022).
  Medline CASGoogle Scholar
• 49. Pratap-Singh A, Guo Y, Lara Ochoa S, Fathordoobady F, Singh A. Optimal ultrasonication process time remains constant for a specific nanoemulsion size reduction system. Sci. Rep. 11(1), 1–12 (2021).
  MedlineGoogle Scholar
• 50. Gupta A, Eral HB, Hatton TA, Doyle PS. Nanoemulsions: formation, properties and applications. Soft Matter 12(11), 2826–2841 (2016).
  Medline CASGoogle Scholar
• 51. Ghiasi Z, Esmaeli F, Aghajani M, Ghazi-Khansari M, Faramarzi MA, Amani A. Enhancing analgesic and anti-inflammatory effects of capsaicin when loaded into olive oil nanoemulsion: an in vivo study. Int. J. Pharm. 559, 341–347 (2019).
  Medline CASGoogle Scholar
• 52. Kwasigroch B, Escribano E, Morán M del C, Queralt J, Busquets MA, Estelrich J. Oil-in-water nanoemulsions are suitable for carrying hydrophobic compounds: indomethacin as a model of anti-inflammatory drug. Int. J. Pharm. 515(1–2), 749–756 (2016).
  Medline CASGoogle Scholar
• 53. Harwansh RK, Deshmukh R, Rahman MA. Nanoemulsion: promising nanocarrier system for delivery of herbal bioactives. J. Drug Deliv. Sci. Technol. 51(February), 224–233 (2019).
  CASGoogle Scholar
• 54. Eissa MM, El-Moslemany RM, Ramadan AA, Amer EI, El-Azzouni MZ, El-Khordagui LK. Miltefosine lipid nanocapsules for single dose oral treatment of Schistosomiasis mansoni: a preclinical study. PLOS ONE 10(11), 1–22 (2015).
  Google Scholar
• 55. Souza ALR, Andreani T, De Oliveira RN et al. In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment. Int. J. Pharm. 463(1), 31–37 (2014).
  MedlineGoogle Scholar
• 56. Xia F, Fan W, Jiang S et al. Size-dependent translocation of nanoemulsions via oral delivery. ACS Appl. Mater. Interfaces 9(26), 21660–21672 (2017).
  Medline CASGoogle Scholar
• 57. Bhattacharjee S. DLS and zeta potential – what they are and what they are not? J. Control. Rel. 235, 337–351 (2016).
  Medline CASGoogle Scholar
• 58. Amara RO, Ramadan AA, El-Moslemany RM, Eissa MM, El-Azzouni MZ, El-Khordagui LK. Praziquantel-lipid nanocapsules: an oral nanotherapeutic with potential Schistosoma mansoni tegumental targeting. Int. J. Nanomed. 13, 4493–4505 (2018).
  Medline CASGoogle Scholar
• 59. Spósito PÁ, Mazzeti AL, de Castro KCMP et al. Higher oral efficacy of ravuconazole in self-nanoemulsifying systems in shorter treatment in experimental chagas disease. Exp. Parasitol. 228, 108142 (2021).
  Medline CASGoogle Scholar
• 60. de Assis DRR, Almeida Oliveira A, Luiz Porto S et al. 4-chlorophenylthioacetone-derived thiosemicarbazones as potent antitrypanosomal drug candidates: investigations on the mode of action. Bioorg. Chem. 113, 105018 (2021).
  MedlineGoogle Scholar
• 61. Silva TC, Mengarda AC, Silva BC et al. New evidence for tamoxifen as an antischistosomal agent: in vitro, in vivo and target fishing studies. Future Med. Chem. 13(11), 945–957 (2021).
  Medline CASGoogle Scholar
• 62. Abbafati C, Machado DB, Cislaghi B et al. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet 396(10258), 1160–1203 (2020).
  MedlineGoogle Scholar
• 63. Pereira VRD, da Silveira LS, Mengarda AC et al. Antischistosomal properties of aurone derivatives against juvenile and adult worms of Schistosoma mansoni. Acta Trop. 213, 105741 (2021).
  Medline CASGoogle Scholar
• 64. Xavier RP, Mengarda AC, Silva MP et al. H1-antihistamines as antischistosomal drugs: in vitro and in vivo studies. Parasit. Vectors 13(1), 1–12 (2020).
  MedlineGoogle Scholar
• 65. Silva LM, Marconato DG, Nascimento da Silva MP et al. Licochalcone A-loaded solid lipid nanoparticles improve antischistosomal activity in vitro and in vivo. Nanomedicine 16(19), 1641–1655 (2021).
  Google Scholar
• 66. De Lima LI, Py-Daniel KR, Guimarães MA et al. Self-nanoemulsifying drug-delivery systems improve oral absorption and antischistosomal activity of epiisopiloturine. Nanomedicine 13(7), 689–702 (2018).
  Google Scholar